RATIONALE: This study found Cystatin SN (CST1), a type 2 cystatin subfamily member, to be highly expressed in nasal polyps from patients with intractable chronic rhinosinusitis with nasal polyps (CRSwNP), using a whole transcript analysis with next-generation sequencing. Eosinophilic chronic rhinosinusitis (ECRS) involves nasal polyps that are refractory and recurrent immediately after endoscopic sinus surgery. We hypothesized that CST1 may contribute to the pathogenesis of ECRS. METHODS: The expression of CST1 in nasal polyps from patients with ECRS was examined by mRNA expression levels, using real-time PCR and immunohistochemistry. We examined the function of CST1 using nasal epithelial cells and nasal fibroblasts. RESULTS: CST1 was significantly expressed in the epithelial cells of the nasal polyps from patients with ECRS, compared with patients who did not have ECRS (non-ECRS). Particularly, CST1 showed very strong expression in patients with severe ECRS. The expression of CST1 may be correlated with the recurring and refractory nature of ECRS. Stimulation by a combination of IL-4 plus dsRNA plus CST1 significantly elevated mRNA expression levels and protein levels of TSLP in nasal epithelial cells. Stimulation by TSLP or IL-33 significantly elevated mRNA expression levels of CST1 in nasal epithelial cells. Stimulation of CST1 significantly elevated mRNA expression levels of CCL11 and POSTN in nasal fibroblasts. CONCLUSIONS: CST1 could amplify eosinophilic infiltration and Th2 inflammation by interacting with epithelial-derived cytokines and fibroblasts on nasal polyps. CST1 may be involved in the pathogenesis of ECRS, and may contribute to the severity and recurrence of CRSwNP after ESS.
The clinical characteristics and pathogenesis of acute exacerbations of chronic rhinosinusitis (AECRS) are poorly understood. Our objective was to identify respiratory viruses during AECRS and measure effects of exacerbations on quality of life (QOL). METHODS: Patients with CRS with or without nasal polyps from a tertiary care allergy-immunology clinic were evaluated for worsening sinonasal symptoms. Visit 1 occurred within 10 days of symptom onset. Visit 2 occurred 6-12 weeks later when symptoms returned to baseline. We detected viruses in nasal lavage via RT-PCR and QOL by SNOT-22 (SinoNasal Outcome Test), WURSS-21 (Wisconsin Upper Respiratory Symptom Survey) and ACQ-6 (Asthma Control Questionnaire). RESULTS: Thirty-eight patients were enrolled. Thirty-two of 38 (84.2%) patients had asthma, 31 (81.6%) received antibiotics, and 28 (73.7%) received prednisone. Viruses were identified in 13/38 (34.2%) at visit 1 (13.2% Rhinovirus A/B/C, remainder Influenza A/B, Adenovirus, Human Coronavirus HKU1/NL63/OC43, Enterovirus or Metapneumovirus) and in 5/26 (19.2%) at visit 2 (7.7% Rhinovirus A/B, remainder Influenza A/B or Human Coronavirus NL63/HKU1). QOL scores were significantly higher at visit 1 compared to visit 2 (SNOT-22 53.8 6 18.2 vs 23.7 6 17.1, p<0.0001, ACQ-6 8.5 6 6.8 vs 3.1 6 3.5, p50.0001, WURSS-21 37.9 6 15.3 vs 1.5 6 5.1, p<0.0001). There was a trend towards higher symptoms scores in patients with viruses at visit 1 compared to those without. Bacterial pathogen analysis is pending. CONCLUSIONS: Our data suggest a role for viral infection in AECRS and possibly in baseline CRS. QOL data demonstrates that significant symptomatic worsening occurred during exacerbations of CRS. 
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